The study published in Genome Medicine investigates the relationship between blood cell composition and DNA methylation age, a biomarker often used to estimate biological age. The research highlights the complexity of this relationship, particularly focusing on how different types of blood cells, such as naïve and memory T cells, contribute to variations in DNA methylation age and age acceleration.
What this study does not show
While the study identifies significant contributions of blood cell composition to DNA methylation age, it does not establish a direct causal relationship between these factors and specific health outcomes.
The researchers developed a principal component analysis (PCA) method to address the collinearity issues often encountered when analyzing blood cell counts. This innovative approach allowed them to quantify how much of the variation in DNA methylation age could be attributed to different blood cell types. They found that up to 53% of the variation in DNA methylation age could be linked to cell counts, with a notable impact from the balance of naïve and memory T cells.
In contrast, the association between age acceleration and blood cell composition was weaker, explaining up to 21% of the variance, and primarily involved neutrophils when considering 2nd-generation epigenetic clocks. The study also validated these findings through experiments using artificial mixtures of cells.
Interestingly, the research revealed that blood cell composition significantly attenuated the association between age acceleration and 176 incident health outcomes. However, this effect was described as modest, indicating that while cell composition plays a role, it may not be the primary driver of health outcomes related to age acceleration.
In conclusion, the findings suggest that DNA methylation age and age acceleration reflect different biological processes, influenced by blood cell composition in distinct ways. The study emphasizes the importance of considering blood cell types when interpreting epigenetic clock data, but also highlights that the contribution of these factors to health outcomes is limited.
Evidence scorecard
- Analytic validity: established
- Clinical validity: partial
- Clinical utility: not established
This evidence is based on primary research involving human participants.